Revised SPC: Libtayo (cemiplimab) 350 mg concentrate for solution for infusion

SPC notes cases of solid organ transplant rejection has been reported in the post-marketing setting (frequency not known). Treatment with cemiplimab may increase the risk of rejection in solid organ transplant recipients therefore risk should be considered in these patients.


electronic Medicines compendium